• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将难溶性碱性药物包封入微球中:一种提高其口服生物利用度的新方法。

Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability.

机构信息

Department of Pharmaceutics, University of London, London WC1N 1AX, UK.

出版信息

Int J Pharm. 2011 Sep 15;416(1):55-60. doi: 10.1016/j.ijpharm.2011.05.079. Epub 2011 Jun 14.

DOI:10.1016/j.ijpharm.2011.05.079
PMID:21679756
Abstract

Poorly water soluble basic drugs are very sensitive to pH changes and following dissolution in the acidic stomach environment tend to precipitate upon gastric emptying, which leads to compromised or erratic oral bioavailability. In this work, we show that the oral bioavailability of a model poorly soluble basic drug (cinnarizine) can be improved by drug encapsulation within highly pH-responsive microparticles (Eudragit L). The latter was prepared by emulsion solvent evaporation which yielded discrete spherical microparticles (diameter of 56.4±6.8μm and a span of 1.2±0.3). These Eudragit L (dissolution threshold pH 6.0) microparticles are expected to dissolve and release their drug load at intestinal conditions. Thus, the enteric microparticles inhibited the in vitro release of drug under gastric conditions, despite high cinnarizine solubility in the acidic medium. At intestinal conditions, the particles dissolved rapidly and released the drug which precipitated out in the dissolution vessel. In contrast, cinnarizine powder showed rapid drug dissolution at low pH, followed by precipitation upon pH change. Oral dosing in rats resulted in a greater than double bioavailability of Eudragit L microparticles compared to the drug powder suspension, although C(max) and T(max) were similar. The higher bioavailability with microparticles contradicts the in vitro results. Such an example highlights that although in vitro results are an indispensable tool for formulation development, an early in vivo assessment of formulation behaviour can provide better prediction for oral bioavailability.

摘要

水溶性差的碱性药物对 pH 值变化非常敏感,在酸性胃环境中溶解后,往往会在胃排空时沉淀,从而导致口服生物利用度降低或不稳定。在这项工作中,我们表明,通过将模型难溶性碱性药物(桂利嗪)包封在对 pH 高度敏感的微颗粒(Eudragit L)内,可以提高其口服生物利用度。后者通过乳液溶剂蒸发制备,得到离散的球形微颗粒(直径为 56.4±6.8μm,范围为 1.2±0.3)。预计这些 Eudragit L(溶解阈值 pH 6.0)微颗粒在肠道条件下溶解并释放其药物负荷。因此,尽管桂利嗪在酸性介质中具有高溶解度,但肠溶微颗粒在胃条件下仍能抑制药物的体外释放。在肠道条件下,颗粒迅速溶解并释放出在溶解容器中沉淀的药物。相比之下,桂利嗪粉末在低 pH 值下迅速溶解药物,然后在 pH 值变化时沉淀。在大鼠体内给药时,与药物粉末混悬液相比,Eudragit L 微颗粒的生物利用度提高了一倍以上,尽管 C(max)和 T(max)相似。微颗粒的较高生物利用度与体外结果相矛盾。这样的例子表明,尽管体外结果是制剂开发不可或缺的工具,但早期的体内评估制剂行为可以更好地预测口服生物利用度。

相似文献

1
Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability.将难溶性碱性药物包封入微球中:一种提高其口服生物利用度的新方法。
Int J Pharm. 2011 Sep 15;416(1):55-60. doi: 10.1016/j.ijpharm.2011.05.079. Epub 2011 Jun 14.
2
Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery.用于靶向胃肠道递送的高pH响应性丙烯酸微颗粒的制备及体内评价
Eur J Pharm Sci. 2009 Jun 28;37(3-4):284-90. doi: 10.1016/j.ejps.2009.02.015. Epub 2009 Mar 6.
3
Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.载塞来昔布结肠靶向性 Eudragit® S100 包衣聚己内酯微球的制备、表征及在大鼠体内的评价。
Drug Deliv. 2011 Sep-Oct;18(7):523-35. doi: 10.3109/10717544.2011.595841. Epub 2011 Jul 28.
4
Spray-drying enteric polymers from aqueous solutions: a novel, economic, and environmentally friendly approach to produce pH-responsive microparticles.从水溶液中喷雾干燥肠溶性聚合物:一种生产 pH 响应性微球的新颖、经济和环保方法。
Eur J Pharm Biopharm. 2011 Oct;79(2):432-9. doi: 10.1016/j.ejpb.2011.03.015. Epub 2011 Mar 23.
5
Inhibiting the gastric burst release of drugs from enteric microparticles: the influence of drug molecular mass and solubility.抑制肠溶微球中药物的胃突释:药物分子量和溶解度的影响。
J Pharm Sci. 2010 Nov;99(11):4576-83. doi: 10.1002/jps.22174.
6
Preparation and characterization of enteric microparticles by coacervation.共沉淀法制备肠溶性微丸及其性质考察。
Drug Dev Ind Pharm. 2013 Jul;39(7):1142-51. doi: 10.3109/03639045.2012.725734. Epub 2012 Sep 25.
7
A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine.用于桂利嗪肠道给药的pH敏感微粒的设计与优化试验。
Drug Deliv Transl Res. 2016 Jun;6(3):195-209. doi: 10.1007/s13346-015-0277-4.
8
Fast-dissolving microparticles fail to show improved oral bioavailability.速溶微粒未能显示出改善的口服生物利用度。
J Pharm Pharmacol. 2006 Oct;58(10):1319-26. doi: 10.1211/jpp.58.10.0004.
9
Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.采用增溶与助溶组合方法提高低水溶性弱碱性化合物的生物利用度:案例研究。
Mol Pharm. 2012 May 7;9(5):1100-8. doi: 10.1021/mp200352q. Epub 2012 Apr 13.
10
Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.采用球形结晶技术制备并评价吡罗昔康与 Eudragit S100 的固体分散体。
Drug Dev Ind Pharm. 2010 Aug;36(8):917-25. doi: 10.3109/03639040903585127.

引用本文的文献

1
Spray-Dried Powders of Casein-Encapsulated Rutin Stabilized With Sugars for the Enhancement of Intestinal Drug Solubility.用糖类稳定的酪蛋白包封芦丁喷雾干燥粉末用于增强肠道药物溶解度
Adv Pharmacol Pharm Sci. 2025 Mar 2;2025:9952737. doi: 10.1155/adpp/9952737. eCollection 2025.
2
In Vitro and In Vivo Evaluations of Berberine-Loaded Microparticles Filled In-House 3D Printed Hollow Capsular Device for Improved Oral Bioavailability.载小檗碱微球的内部 3D 打印中空胶囊装置的体外和体内评价:改善口服生物利用度。
AAPS PharmSciTech. 2022 Mar 16;23(4):89. doi: 10.1208/s12249-022-02241-9.
3
Stabilization benefits of single and multi-layer self-nanoemulsifying pellets: A poorly-water soluble model drug with hydrolytic susceptibility.
单层和多层自微乳载药丸的稳定性优势:具有水解易感性的低水溶性模型药物。
PLoS One. 2018 Jul 19;13(7):e0198469. doi: 10.1371/journal.pone.0198469. eCollection 2018.
4
Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine.用于提高桂利嗪生物利用度的胃滞留微球的设计与优化。
Drug Deliv Transl Res. 2016 Jun;6(3):210-24. doi: 10.1007/s13346-016-0280-4.
5
A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine.用于桂利嗪肠道给药的pH敏感微粒的设计与优化试验。
Drug Deliv Transl Res. 2016 Jun;6(3):195-209. doi: 10.1007/s13346-015-0277-4.
6
Development of intramammary delivery systems containing lasalocid for the treatment of bovine mastitis: impact of solubility improvement on safety, efficacy, and milk distribution in dairy cattle.开发含拉沙洛西用于治疗奶牛乳腺炎的乳房内给药系统:溶解度改善对奶牛安全性、疗效及乳汁分布的影响
Drug Des Devel Ther. 2015 Jan 22;9:631-42. doi: 10.2147/DDDT.S74731. eCollection 2015.
7
Recent advances in delivery systems and therapeutics of cinnarizine: a poorly water soluble drug with absorption window in stomach.桂利嗪给药系统与治疗方法的最新进展:一种胃内有吸收窗的难溶性药物
J Drug Deliv. 2014;2014:479246. doi: 10.1155/2014/479246. Epub 2014 Nov 13.
8
Encapsulation and Delivery of Crystalline Hydrophobic Nutraceuticals using Nanoemulsions: Factors Affecting Polymethoxyflavone Solubility.使用纳米乳液对结晶疏水性营养保健品进行包封与递送:影响多甲氧基黄酮溶解度的因素
Food Biophys. 2012 Dec 1;7(4):341-353. doi: 10.1007/s11483-012-9272-1.